Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes

por Howes, Oliver D., Cummings, Connor, Chapman, George E., Shatalina, Ekaterina
Publicado 2022

O5.5. THE NEUROBIOLOGY OF NEGATIVE SYMPTOMS IN SCHIZOPHRENIA: MULTI-MODAL PET AND FMRI FINDINGS

por Howes, Oliver, Ashok, Abhishekh, Shatalina, Ekaterina, Rabiner, Eugenii, Reis Marques, Tiago
Publicado 2020

Reward processing in schizophrenia and its relation to Mu opioid receptor availability and negative symptoms: A [(11)C]-carfentanil PET and fMRI study

por Shatalina, Ekaterina, Ashok, Abhishekh H., Wall, Matthew B., Nour, Matthew M., Myers, Jim, Reis Marques, Tiago, Rabiner, Eugenii A., Howes, Oliver D.
Publicado 2023

O11.3. SYNAPTIC MARKER PROTEIN SV2A IS REDUCED IN SCHIZOPHRENIA IN VIVO AND UNAFFECTED BY ANTIPSYCHOTICS IN RATS

por Chika Onwordi, Ellis, Halff, Els, Whitehurst, Thomas, Mansur, Ayla, Cotel, Marie-Caroline, Wells, Lisa, Creeney, Hannah, Bonsall, David, Rogdaki, Maria, Shatalina, Ekaterina, Reis Marques, Tiago, Rabiner, Eugenii, Gunn, Roger, Natesan, Sridhar, Vernon, Anthony, Howes, Oliver D
Publicado 2020

Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats

por Onwordi, Ellis Chika, Halff, Els F., Whitehurst, Thomas, Mansur, Ayla, Cotel, Marie-Caroline, Wells, Lisa, Creeney, Hannah, Bonsall, David, Rogdaki, Maria, Shatalina, Ekaterina, Reis Marques, Tiago, Rabiner, Eugenii A., Gunn, Roger N., Natesan, Sridhar, Vernon, Anthony C., Howes, Oliver D.
Publicado 2020